Seeking Alpha
 

Johnson & Johnson (JNJ)

- NYSE
  • Tue, Jan. 20, 8:44 AM
    • Johnson & Johnson (NYSE:JNJ) notable changes in Q4 by segment ($M):
    • Consumer (-3.9%): Women's Health (-11.5%); Baby Care: (-10.4%); Wound Care: (-6.2%).
    • Pharmaceutical (+9.6%); Immunology (+7.3%), Simponi/Simponi Aria: 346 (+36.2%), Stelara: 545 (+30.7%), Remicade: 1,672 (-2.3%).
    • Infectious Diseases (+13.9%); Olysio/Sovriad: 321 (+999%), Edurant: 90 (+23.3%), Prezista: 448 (-2.8%), Other: 212 (-24.6%), Incivo: 5 (-95.3%).
    • Neuroscience: 1,651 (unch); Invega Sustenna/Xeplion: 418 (+19.4%), Invega: 161 (+4.5%), Other: 609 (-7.3%), Risperda Consta: 294 (-8.4%).
    • Oncology: 1,212 (+8.9%); Other: 199 (+111.7%), Zytiga: 595 (+20.2%), Velcade: 418 (-20.2%).
    • Other:  1,482 (+28.1%), Xarelto: 428 (+57.9%), Other: 752 (+29.9%), Procrit/Eprex: 302 (-1.6%).
    • Med Devices & Diag: 6,649 (-9.0%); Specialty Surgery/Other: 904 (+32.4%), Cardiovascular Care: 558 (+4.5%), Orthopedics: 2,441 (-0.6%), Surgical Care: 1,572 (-4.1%), Diabetes Care: 514 (-8.7%), Vision Care: 646 (-10.2%), Diagnostics: 14 (-97.0%).
    | Comment!
  • Tue, Jan. 20, 8:21 AM
    • Johnson & Johnson (NYSE:JNJ) Q4 results ($M): Total Revenues: 18,254 (-0.6%), Consumer: 3,606 (-3.9%), Pharmaceutical: 7,999 (+9.6%), Medical Devices & Diagnostics: 6,649 (-9.0%).
    • Revenue by region: U.S.: 8,604 (+7.4%), Europe: 4,560 (-8.2%), W. Hemisphere ex. U.S.: 1,782 (-5.8%), Asia Pacific & Africa: 3,308 (-5.0%).
    • COGS: 5,853 (-1.7%); R&D Expense: 2,635 (+9.3%); SG&A Expense: 5,822 (-1.6%); Net Income: 2,521 (-28.4%); EPS: 0.89 (-27.6%); Gross Profit: 12,401 (unch); COGS: 32.1% (-1.2%); Gross Margin: 67.9% (+0.6%); Operating Income: 3,944 (-3.1%); Operating Income Yield: 21.6% (-2.6%); Net Earnings Yield: 13.8% (-28.0%).
    • 2015 non-GAAP EPS guidance: $6.12 - 6.27.
    | Comment!
  • Tue, Jan. 20, 7:51 AM
    • Johnson & Johnson (NYSE:JNJ): Q4 EPS of $1.27 beats by $0.01.
    • Revenue of $18.25B (-0.6% Y/Y) misses by $310M.
    • Shares -0.04% PM.
    • Press Release
    | 2 Comments
  • Mon, Jan. 19, 5:30 PM
  • Dec. 17, 2014, 11:30 AM
    • Johnson & Johnson (JNJ +0.4%) will report Q4 and full-year results on January 20 before the open. The conference call will begin at 8:30 am ET.
    • Consensus views for Q4 and 2014 are EPS of $1.26 and $5.96 on revenues of $18.6B and $74.8B, respectively.
    | 2 Comments
  • Oct. 14, 2014, 8:37 AM
    • Johnson & Johnson (NYSE:JNJ) Q3 results by selected line item:
    • Consumer: Leaders: OTC Intl: +6.2%; OTC WW: +4.5%; Oral Care - U.S.: +4.2%; Oral Care Intl: +3.2%. Laggards: Women's Health - U.S.: -89.6%; Women's Health WW: -20.3%; Women's Health Intl: -4.2%; Wound Care/Other Intl: -3.2%.
    • Pharmaceuticals: Leaders: Infectious Diseases WW: +90.1%; Edurant U.S.: +75.0%; Xarelto U.S.: +68.3%;  Edurant Intl: +58.3%; Stelara U.S.: +52.8%; Oncology U.S.: +34.4%. Laggards: Incivo Intl: -50.0%; Other Infectious Diseases Intl: -41.5%; Risperdal Consta Intl: -16.5%; Other Neuroscience U.S.: -13.9%; Concerta/Methylphenidate U.S.: -10.5%.
    • Medical Devices and Diagnostics: Leaders: Cardiovascular Care U.S.: +12.8%; Cardiovascular Care Intl: +5.2%; Orthopaedics U.S.: +3.2%; Diabetes Care: +3.0%. Laggards: Diagnostics WW: -90.4%; Diagnostics Intl: -81.4%; Vision Care U.S.: -12.5%; Vision Care WW: -5.9%; Surgical Care U.S.: -3.9%.
    | Comment!
  • Oct. 14, 2014, 8:14 AM
    • Johnson & Johnson (NYSE:JNJ) Q3 results: Total Revenues: $18,467M (+5.1%); Consumer: $3,589M (-0.6%); Pharmaceutical: $8,307M (+18.1%); Med Device & Diagnostics: $6,571M (-5.2%).
    • Revenue by geographic segment: U.S.: $8,842M (+11.6%); Europe: $4,446M (-0.7%); Western Hemisphere ex-U.S.: $1,820M (-1.2%); Asia-Pacific/Africa: $3,359M (+0.9%); International: $9,625M (-0.3%); Worldwide: $18,467 (+5.1%).
    • COGS: $5,399M (+1.0%); R&D Expense: $2,023M (-0.9%); SG&A Expense: $5,468M (+2.9%); Net Income: $4,749M (+59.3%); EPS: $1.66 (+59.6%).
    • Gross Profit: $13,068M (+6.8%); COGS: 29.2% (-3.9%); Gross Margin: 70.8% (+1.7%); Operating Profit: $5,577M (+14.4%); Operating Earnings Yield: 30.2% (+8.9%); Net Earnings Yield: 25.7% (+51.6%).
    • 2014 EPS guidance raised to $5.92 - 5.97 from $5.85 - 5.92.
    | Comment!
  • Oct. 14, 2014, 7:48 AM
    • Johnson & Johnson (NYSE:JNJ): Q3 EPS of $1.50 beats by $0.06.
    • Revenue of $18.47B (+5.1% Y/Y) beats by $90M.
    • Shares +0.9% PM.
    • Press Release
    | Comment!
  • Oct. 13, 2014, 5:30 PM
  • Sep. 23, 2014, 5:03 PM
    • Johnson & Johnson (JNJ -0.4%) will hold its Q3 earnings conference call on October 14 at 8:30 am ET.
    • Consensus view is EPS of $1.43 on revenues of $18.4B.
    | Comment!
  • Jul. 15, 2014, 8:04 AM
    • Johnson & Johnson (NYSE:JNJ) Q2 results: Revenues: Consumer: $3,744M (+2.4%), Pharmaceutical: $8,509M (+21.1%), Med Devices & Diagnostics: $7,242M (+0.7%); Global Business: $19,495M (+9.1%).
    • COGS: $6,039M (+10.0%); R&D Expense: $2,005M (+3.0%); SG&A Expense: $5,481M (+2.0%); Net Income: $4,326M (+12.9%); EPS: $1.51 (+13.5%).
    • Gross Profit: $13,456M (+8.6%); COGS%: 31.0% (+0.9%); Gross Margin%: 69.0% (-0.4%); Operating Profit: $5,970 (+17.8%); Operating Earnings Yield: 30.6% (+8.1%); Net Earnings Yield: 22.2% (+3.5%).
    • EPS guidance raised to $5.85 - 5.92 from $5.80 - 5.90.
    • Press release
    | 10 Comments
  • Jul. 15, 2014, 7:46 AM
    • Johnson & Johnson (NYSE:JNJ): Q2 EPS of $1.66 beats by $0.11.
    • Revenue of $19.49B (+9.0% Y/Y) beats by $550M.
    • Press Release
    | 3 Comments
  • Jul. 14, 2014, 5:30 PM
  • Apr. 15, 2014, 7:46 AM
    • Johnson & Johnson (JNJ): Q1 EPS of $1.54 beats by $0.06.
    • Revenue of $18.11B (+3.5% Y/Y) beats by $110M.
    • Press Release
    | 7 Comments
  • Apr. 15, 2014, 12:05 AM
  • Apr. 14, 2014, 5:30 PM
Visit Seeking Alpha's
JNJ vs. ETF Alternatives
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale ofproducts in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.